Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(14):1039; doi:10.1093/jnci/94.14.1039-b
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

Journal of the National Cancer Institute, Vol. 94, No. 14, 1039, July 17, 2002
© 2002 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Adjuvant Therapy in Postmenopausal Women

Whether postmenopausal women with lymph node-negative breast cancer should be given adjuvant chemotherapy is controversial. The International Breast Cancer Study Group (IBCSG) (p. 1054) launched a randomized trial to evaluate the role of adjuvant chemotherapy followed by tamoxifen compared with tamoxifen alone in 1669 postmenopausal women with lymph node-negative disease. The IBCSG found that the benefit of chemotherapy was statistically significantly dependent on the estrogen receptor (ER) status of the tumor. They found that patients with ER-negative tumors had substantially better survival with chemotherapy followed by tamoxifen than with tamoxifen . . . [Full Text of this Article]

Death and Cancer-Directed Surgeries

New Diagnostic Marker for Bladder Cancer

Glucose Transporter 1 and Matrix Metalloproteinase 2

DNA Repair and Non-Small Cell Lung Cancer

Insulin-Like Growth Factor I Pathway and Prostate Cancer